Compare Ascendis Pharma A/S (ASND) vs HubSpot Inc (HUBS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs HubSpot Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while HubSpot Inc trades at $209.03 (market cap $10.62B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| ASND | HUBS | |
|---|---|---|
Market Cap | $17.74B | $10.62B |
Sector | Health | Technology |
52-Week High | $277.18 | $560.90 |
52-Week Low | $163.32 | $170.39 |
Enterprise Value | $18.11B | $9.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
HubSpot (HUBS) trades at $207.48, up 0.74% on the day, showing bullish momentum with strong technical support at $200 and resistance at $213. The company demonstrates robust revenue growth, reaching $3.13 billion in 2025, and has consistently beaten earnings expectations. Analyst sentiment is overwhelmingly positive with an 80.85% buy rating and a consensus price target of $273.53, indicating significant upside potential from current levels.
The outlook for HUBS remains favorable due to accelerating AI integration and customer growth, though high valuation multiples (P/E of 109.2) pose risks if growth slows. Competitive pressures in the CRM space and macroeconomic headwinds could challenge future performance, but strong cash flow generation and expanding margins support a bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
